ATE332364T1 - Verfahren zur gewinnung von purifizierter virenzuammensetzung - Google Patents

Verfahren zur gewinnung von purifizierter virenzuammensetzung

Info

Publication number
ATE332364T1
ATE332364T1 AT00906444T AT00906444T ATE332364T1 AT E332364 T1 ATE332364 T1 AT E332364T1 AT 00906444 T AT00906444 T AT 00906444T AT 00906444 T AT00906444 T AT 00906444T AT E332364 T1 ATE332364 T1 AT E332364T1
Authority
AT
Austria
Prior art keywords
purified virus
virus composition
obtaining purified
viral
particles
Prior art date
Application number
AT00906444T
Other languages
English (en)
Inventor
Michel Koehl
David Gaillac
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE332364T1 publication Critical patent/ATE332364T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10051—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00906444T 1999-02-22 2000-02-21 Verfahren zur gewinnung von purifizierter virenzuammensetzung ATE332364T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9902167 1999-02-22

Publications (1)

Publication Number Publication Date
ATE332364T1 true ATE332364T1 (de) 2006-07-15

Family

ID=9542357

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00906444T ATE332364T1 (de) 1999-02-22 2000-02-21 Verfahren zur gewinnung von purifizierter virenzuammensetzung

Country Status (8)

Country Link
US (1) US7264958B1 (de)
EP (1) EP1155120B1 (de)
JP (2) JP4802366B2 (de)
AT (1) ATE332364T1 (de)
AU (1) AU774437B2 (de)
CA (1) CA2364934C (de)
DE (1) DE60029195T2 (de)
WO (1) WO2000050573A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139040A0 (en) 1998-04-22 2001-11-25 Genvec Inc Efficient purification of adenovirus
JP5322252B2 (ja) * 2001-12-20 2013-10-23 バヴァリアン・ノルディック・アクティーゼルスカブ 感染細胞からのポックスウイルスの採取および精製法
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
US20070207461A1 (en) 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
CA2602944C (en) 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
JP4670583B2 (ja) * 2005-10-20 2011-04-13 チッソ株式会社 水溶性カチオン性磁気微粒子を用いた脂質ベシクルの分離又は検出方法
WO2008008872A2 (en) * 2006-07-14 2008-01-17 Wisconsin Alumni Research Foundation Adsorptive membranes for trapping viruses
CL2008000249A1 (es) 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
US10041049B2 (en) 2008-11-03 2018-08-07 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
AU2010206195B2 (en) 2009-01-20 2016-03-10 Transgene Sa Soluble ICAM-1 as biomarker for prediction of therapeutic response
ES2555858T3 (es) 2009-03-24 2016-01-11 Transgene Sa Biomarcador para el control de pacientes
PL2419728T3 (pl) 2009-04-17 2014-05-30 Transgene Sa Biomarker do monitorowania pacjentów
CN102483405B (zh) 2009-07-10 2015-12-02 特朗斯吉有限公司 用于选择患者的生物标志物及相关方法
RU2555346C2 (ru) 2009-08-07 2015-07-10 Трансген Са Композиция для лечения инфекции вирусом гепатита в
MX2012007936A (es) 2010-02-15 2012-11-22 Crucell Holland Bv Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus.
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CA2816190C (en) * 2010-10-27 2020-03-24 Philip Morris Products S.A. Methods for capturing virus like particles from plants using expanded bed chromatography
CA2819552C (en) 2010-12-09 2023-09-26 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
TW201318637A (zh) 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
TWI638829B (zh) 2012-07-10 2018-10-21 法商傳斯堅公司 分枝桿菌抗原疫苗
EP3587455A1 (de) 2012-10-23 2020-01-01 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
CA2914790C (en) 2013-06-14 2024-02-27 Psioxus Therapeutics Limited A dosing regime and formulations for type b adenoviruses
HUE035875T2 (hu) 2013-10-25 2018-06-28 Psioxus Therapeutics Ltd Heterológ géneket tartalmazó onkolitikus adenovírusok
WO2015104380A1 (en) 2014-01-09 2015-07-16 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
EP4523756A3 (de) 2015-02-13 2025-05-28 Transgene Immunotherapeutischer impfstoff und antikörperkombinationstherapie
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
BR112018012180A2 (pt) 2015-12-17 2018-12-04 Psioxus Therapeutics Ltd vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
IL303187A (en) 2016-08-29 2023-07-01 Akamis Bio Ltd Adenovirus with bispecific T cell activator
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
WO2018069316A2 (en) 2016-10-10 2018-04-19 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
IL270024B2 (en) 2017-04-22 2025-04-01 Immunomic Therapeutics Inc LAMP structures and their use in vaccination
KR20200016224A (ko) 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
EP3793595A1 (de) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Verbesserte lamp-konstrukte mit allergenen
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
WO2020061528A1 (en) 2018-09-21 2020-03-26 University Of Connecticut Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome
AU2019382919A1 (en) * 2018-11-22 2021-05-27 Fixed Phage Limited Production of immobilised bacteriophage
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP3921413A1 (de) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanisierte zelllinie
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
GB201909081D0 (en) * 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
JP2022551732A (ja) 2019-10-18 2022-12-13 イミュノミック セラピューティックス， インコーポレイテッド がん抗原を含む改良ｌａｍｐ構築物
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
WO2021209897A1 (en) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
EP4175664A2 (de) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostata-neoantigene und ihre verwendungen
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
US20230241530A1 (en) * 2022-02-01 2023-08-03 W. L. Gore & Associates, Inc. Affinity chromatography devices containing a heat treated fibrillated polymer membrane for the separation of mrna and viral vectors from an aqueous mixture
EP4508071A1 (de) 2022-04-10 2025-02-19 Immunomic Therapeutics, Inc. Bicistronische lampenkonstrukte mit immunreaktionserhöhenden genen und verfahren zur verwendung davon
WO2025158316A1 (en) 2024-01-26 2025-07-31 Janssen Biotech, Inc. Ovarian neoantigens and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0328256A1 (de) * 1988-01-21 1989-08-16 Owens-Corning Fiberglas Corporation Glasfaser, überzogen mit Agarose, zur Verwendung als Säulenpackung oder chromatographisches Medium in Biotrennungen
GB8806605D0 (en) 1988-03-19 1988-04-20 Robinson E Composite adsorbents
SE9101149D0 (sv) * 1991-04-17 1991-04-17 Pharmacia Lkb Biotech Beads for down stream processing
DE4128953A1 (de) 1991-08-30 1993-03-04 Basf Ag Verfahren zur kultivierung von saeugerzellen im fliessbettreaktor
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
WO1997008298A1 (en) * 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
AU2660397A (en) * 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
IL127692A0 (en) 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
WO1998022588A2 (en) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
AU5370598A (en) 1996-12-13 1998-07-03 Schering Corporation Methods for purifying viruses
SE9700383D0 (sv) * 1997-02-04 1997-02-04 Pharmacia Biotech Ab An adsorption/separation method and a medium for adsorption/separation
WO1999040702A1 (en) 1998-02-04 1999-08-12 Sun Microsystems, Inc. Method and apparatus for efficient authentication and integrity checking using hierarchical hashing
IL139040A0 (en) 1998-04-22 2001-11-25 Genvec Inc Efficient purification of adenovirus

Also Published As

Publication number Publication date
EP1155120A1 (de) 2001-11-21
JP2011120596A (ja) 2011-06-23
DE60029195D1 (de) 2006-08-17
EP1155120B1 (de) 2006-07-05
DE60029195T2 (de) 2007-06-28
AU2811800A (en) 2000-09-14
AU774437B2 (en) 2004-06-24
JP2002536992A (ja) 2002-11-05
CA2364934C (fr) 2011-10-18
JP4802366B2 (ja) 2011-10-26
WO2000050573A1 (fr) 2000-08-31
CA2364934A1 (fr) 2000-08-31
US7264958B1 (en) 2007-09-04

Similar Documents

Publication Publication Date Title
DE60029195D1 (de) Verfahren zur gewinnung von purifizierter virenzuammensetzung
ATE324436T1 (de) Verfahren zur reinigung von menschlichen, dem papillomavirus ähnlichen partikeln.
ATE306252T1 (de) Verfahren zur herstellung kristalliner partikel zur inhalation
ATE278785T1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
ATE322252T1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
DE60114348D1 (de) Verfahren zur Reinigung von Gasen
DE69637509D1 (de) Verfahren zur reinigung von faktor-ix
DE69908998D1 (de) Verfahren zur Herstellung von Kohlenstoff
DE69703957D1 (de) Verfahren zur Herstellung von kristallinen Ceroxidteilchen.
DE59800264D1 (de) Verfahren zur Herstellung von SiO2-Granulat
DE60132094D1 (de) Verfahren zur Herstellung von gereinigten Partikeln
DE60212062D1 (de) Verfahren zur Herstellung von porösen Polyesterpartikeln
DE60330146D1 (de) Verfahren zur reinigung von fibrinogen
DE60203975D1 (de) Verfahren zur Herstellung von magnetischen Teilchen, magnetische Teilchen und magnetischer Werkstoff
DE69531308D1 (de) Verfahren zur Herstellung von gereinigten papillomavirus Proteinen
DE60011396D1 (de) Verfahren zur herstellung von iopamidol
AU2003279240A1 (en) Methods for purifying viral particles for gene therapy
ATE509889T1 (de) Verfahren zur herstellung von granulatförmigem umhüllten natriumpercarbonat und verfahrensgemäss erhältliches produkt
DE60129907D1 (de) Verfahren zur Reinigung von Isophthalonitril
DE69931976D1 (de) Verfahren zur Herstellung von Aminophosphinen und Aminophosphinoxiden, Zwischenprodukte dafür
DE60032077D1 (de) Verfahren zur dehalogenierung von kohlenwasserstoffhaltigen kohlenstoff-kohlenstoff doppelbindungen
DE59912502D1 (de) Verfahren zur herstellung von enantiomerenreinem n-methyl- n- (1s)- 1-phenyl- 2-((3s)-3- hydroxypyrrolidin- 1-yl)ethyl]- 2,2- diphenylacetamid
DE19983485T1 (de) Verfahren zur Herstellung von Gasfedern
DE60143437D1 (de) Katalytisches verfahren zur herstellung von thiazolderivaten
DE50106581D1 (de) Verfahren zur modifizierung der oberflächen von feinporösen adsorbentien

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1155120

Country of ref document: EP